Nonredundant Roles for CD1d-restricted Natural Killer T Cells and Conventional CD4+ T Cells in the Induction of Immunoglobulin E Antibodies in Response to Interleukin 18 Treatment of Mice

Tomohiro Yoshimoto,1,2 Booki Min,3 Takaaki Sugimoto,1,2 Nobuki Hayashi,1,2 Yuriko Ishikawa,1,2 Yuki Sasaki,1,2 Hitomi Hata,1,2 Kazuyoshi Takeda,4 Ko Okumura,4 Luc Van Kaer,5 William E. Paul,3 and Kenji Nakanishi1,2

1Department of Immunology and Medical Zoology, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan
2Core Research for Evolutional Science and Technology, Japan Science and Technology Corporation, Saitama 332-0012, Japan
3Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892
4Department of Immunology, Juntendo University School of Medicine, Tokyo 113-8421, Japan
5Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232

Abstract
Interleukin (IL)-18 synergizes with IL-12 to promote T helper cell (Th)1 responses. Somewhat paradoxically, IL-18 administration alone strongly induces immunoglobulin (Ig)E production and allergic inflammation, indicating a role for IL-18 in the generation of Th2 responses. The ability of IL-18 to induce IgE is dependent on CD4+ T cells, IL-4, and signal transducer and activator of transcription (stat)6. Here, we show that IL-18 fails to induce IgE both in CD1d−/− mice that lack natural killer T (NKT) cells and in class II−/− mice that lack conventional CD4+ T cells. However, class II−/− mice reconstituted with conventional CD4+ T cells show the capacity to produce IgE in response to IL-18. NKT cells express high levels of IL-18 receptor (R)α chain and produce significant amounts of IL-4, IL-9, and IL-13, and induce CD40 ligand expression in response to IL-2 and IL-18 stimulation in vitro. In contrast, conventional CD4+ T cells express low levels of IL-18Rα and poorly respond to IL-2 and IL-18. Nevertheless, conventional CD4+ T cells are essential for B cell IgE responses after the administration of IL-18. These findings indicate that NKT cells might be the major source of IL-4 in response to IL-18 administration and that conventional CD4+ T cells demonstrate their helper function in the presence of NKT cells.

Key words: IL-18R • CD4+ NK1.1+ T cells • Th2 cytokines • CD40 ligand • allergy

Introduction
IL-18, an IL-1–like cytokine that requires cleavage by caspase-1 to become active, was originally identified as a factor that enhances IFN-γ production by Th1 cells in the presence of anti-CD3 Ab plus IL-12 (1, 2). Later studies have revealed that IL-18 and IL-12 directly and synergistically induce IFN-γ production by Th1 cells, nonpolarized T cells, B cells, NK cells, macrophages, and dendritic cells (3–8). However, our recent studies and those of others have demonstrated that in the absence of IL-12, IL-18 promotes Th2 cytokine production by T cells, basophils, and mast cells (9–13). In the presence of IL-3, IL-18 stimulates basophils and mast cells to produce IL-4 and IL-13 even without FceR cross-linkage (9). CD4+ T cells cultured with IL-2 and IL-18, without TCR engagement, express CD40 ligand (L)* produce IL-4 and IL-13, and induce B cells to secrete IgE in vitro (10). Consistent with these findings, the administration of relatively high doses of IL-18,
which have the ability to induce Th1 diseases when administered with IL-12 to WT mice (14), results in striking increases in serum IgE that are dependent on CD4+ T cells, IL-4, and signal transducer and activator of transcription 6 but are independent of TCR engagement (10). Transgenic (Tg) mice that overexpress IL-18 or caspase-1 in their keratinocytes (KIL-18Tg and KCASP1Tg, respectively) spontaneously produce IgE in an endogenous IL-18–dependent manner (10, 15, 16). Taken together, these results suggest that IL-18 promotes allergic disorders, particularly intrinsic type atopic diseases characterized by the absence of sensitivity to a particular antigen.

Although it is well established that IL-18 stimulates CD4+ T cells to produce IL-4 in vivo and in vitro, the CD4+ T cell subset that responds to IL-18 in vivo by inducing IL-4 production and CD40L expression remains unknown. NKT cells express the NK cell marker NK1.1 and an invariant Vα8.2 chain, preferentially associated with a nonpolymorphic MHC class I–like molecule CD1d (17) and recognize glycolipids, such as α-galactosylerceramide (α-GalCer) presented by CD1d (18). ~60% of all NKT cells express CD4 whereas the remaining cells are CD4− CD8− (17). NKT cells exert regulatory functions, which are most likely mediated by their capacity to promptly release large amounts of IL-4 and IFN-γ upon TCR engagement by anti-CD3 or NKT cell Ls such as α-GalCer (19–22). Modulation of NKT cells may not only determine the outcome of host immune response, but also be applicable for the treatment of immunological diseases. Furthermore, it is important to determine the stimulus that selectively induces NKT cells to produce Th1 or Th2 cytokines.

Here we demonstrate that IL-18 treatment of mice induces CD40L expression and IL-4 production by NKT cells in vivo. NKT cell–deficient (CD1d-deficient; CD1d−/−) mice or conventional CD4+ T cells–deficient (class II–deficient; class II−/−) mice fail to produce IgE in response to injection of IL-18 whereas class II−/− mice reconstituted with conventional CD4+ T cells produce a substantial amount of IgE. Culturing NKT cells with IL-2 and IL-18, without TCR engagement, causes a striking increase in CD40L expression and production of significant amounts of IL-4, IL-9, and IL-13 by these cells. Although conventional CD4+ NKT cell−/− T cells respond poorly to IL-18 with relatively modest induction of IL-4 and CD40L, they are required for IgE production in response to IL-18 in vivo, as shown by the failure of class II−/− mice reconstituted with conventional CD4+ T cells from IL-4−/− mice to produce IgE when treated with IL-18. These results indicate that NKT cells are a critical subset of CD4+ T cells that respond to IL-18 by expression of Th2 cytokines and CD40L in vivo, and conventional CD4+ T cells act as Th cells together with NKT cells in IL-18–induced IgE responses.

Materials and Methods

Mice and Reagents. Specific pathogen-free female BALB/c and C57BL/6 mice, and C57BL/6 class II−/− mice at 8 wk of age were purchased from The Jackson Laboratory. C57BL/6 IL-4−/− mice were obtained from Taconic Farms. Mice Tg for αβ TCR recognizing OVA233–249 (DO11.10; BALB/c genetic background) were provided by D. Loh (Washington University, St. Louis, MO). The generation of C57BL/6 CD1d−/− mice was previously described (23). Recombinant mouse IL-18 and anti–mouse IL-18Ra chain mAb (Y38; reference 24) were provided by Hayashibara Biochemical Laboratories Inc. FITC–anti-mouse CD4 (GK1.5), FITC–anti–mouse CD44 (IM7), FITC–anti–rat IgG1 (R511/39.4), FITC–anti-mouse IL-4 (BVD4-1D11), CyChrome–anti–mouse CD4 (RM4-5), biotinylated anti–mouse CD40L, PE–anti–mouse NK1.1 (PK136), and PE-labeled streptavidin were purchased from BD Biosciences.

Preparation of NKT Cells. Splenic CD4+ T cells from C57BL/6 mice were purified by MicroBeads (anti–mouse CD4, clone RM4-5; Miltenyi Biotec). The enriched CD4+ T cells were first treated with 10 μg/ml anti-CD4/III (anti-CD4, clone RM4-5; Miltenyi Biotec) followed by treatment with FITC–anti–CD4 and PE–anti–CD40L (anti–CD40L, GK1.5). Cells were then stained with FITC–anti–CD44 and PE–anti-NK1.1, and CD44− NK1.1+ T cells were sorted using a fluorescence cell sorter (Elite; Coulter Electronics).

Materials and Methods

Role of NKT Cells in IL-18–induced IgE Production

Mice and Reagents. Specific pathogen-free female BALB/c and C57BL/6 mice, and C57BL/6 class II−/− mice at 8 wk of age were purchased from The Jackson Laboratory. C57BL/6 IL-4−/− mice were obtained from Taconic Farms. Mice Tg for αβ TCR recognizing OVA233–249 (DO11.10; BALB/c genetic background) were provided by D. Loh (Washington University, St. Louis, MO). The generation of C57BL/6 CD1d−/− mice was previously described (23). Recombinant mouse IL-18 and anti–mouse IL-18Ra chain mAb (Y38; reference 24) were provided by Hayashibara Biochemical Laboratories Inc. FITC–anti-mouse CD4 (GK1.5), FITC–anti–mouse CD44 (IM7), FITC–anti–rat IgG1 (R511/39.4), FITC–anti-mouse IL-4 (BVD4-1D11), CyChrome–anti–mouse CD4 (RM4-5), biotinylated anti–mouse CD40L, PE–anti–mouse NK1.1 (PK136), and PE-labeled streptavidin were purchased from BD Biosciences.

Preparation of NKT Cells. Splenic CD4+ T cells from C57BL/6 mice were purified by MicroBeads (anti–mouse CD4, clone RM4-5; Miltenyi Biotec). The enriched CD4+ T cells were first treated with 10 μg/ml anti-CD4/III (anti-CD4, clone RM4-5; Miltenyi Biotec) followed by treatment with FITC–anti–CD4 and PE–anti–CD40L (anti–CD40L, GK1.5). Cells were then stained with FITC–anti–CD44 and PE–anti-NK1.1, and CD44− NK1.1+ T cells were sorted using a fluorescence cell sorter (Elite; Coulter Electronics).
tion with 4% (wt/vol) paraformaldehyde in PBS and permeabilization of cell membrane with ice-cold PBS containing 1% FCS plus 0.1% saponin. Resultant cells were further stained with 0.5 μg FITC-anti–mouse IL-4 or isotype-matched control Ab and analyzed for their proportion of cytoplasmic IL-4+ cells by FACS-Calibur® (Becton Dickinson). To detect CD40L+ cells in mice treated with IL-18, total spleen cells were stained with FITC–anti-CD4, PE–anti-NK1.1, and the combination of biotinylated anti-CD40L and tri-color streptavidin (Caltag), and then analyzed on a FACS-Calibur®.

For determination of IL-18Rα chain expression on NKT cells, after FcR blocking with anti-FcγRII/III, splenic lymphocytes were incubated with anti–mouse IL-18Rα chain mAb or control rat IgG1 mAb (R3-34) for 30 min at 4°C, followed by FITC-conjugated anti-rat IgG1 mAb, PE–anti-NK1.1, and Cy-Chrome–anti–mouse CD4 for 30 min at 4°C in staining buffer. Samples were analyzed on a FACS-Calibur®.

Results

CD1−/− Mice Are Defective in the Production of Th2 Cytokines and IgE in Response to IL-18 Administration. IL-18 treatment of BALB/c mice induces IgE in a CD4+ T cell–dependent manner (10). Consistent with our previous report (10), this IgE response is not associated with induction of Th2 cells (not depicted), suggesting that TCR engagement might not be required for IgE induction in IL-18–injected mice. To further substantiate this observation that IgE response is independent of TCR engagement by endogenous Ags, we examined the capacity of BALB/c mice expressing transgene–encoding TCR for OVA peptide (DO11.10 mice) to produce IgE in response to IL-18. These mice received daily injections of IL-18 (2 μg/day) for 13 d. Like normal BALB/c mice, they produced IgE in response to this treatment (Fig. 1 A), although this IL-18 treatment again did not induce Th2 response (not depicted). Furthermore, this IL-18–induced IgE production was entirely resistant to cyclosporin A treatment (not depicted), further excluding the involvement of TCR–mediated T cell activation in this T cell–dependent IgE response. To identify the IL-18–responsive T cells that are relevant in IL-18–induced IgE response, we compared the capacity of C57BL/6 and C57BL/6 background CD1−/− mice lacking CD4+ NK1.1+ T cells (23) to produce IgE in response to IL-18. As shown in Fig. 1 B, IL-18 caused a striking increase in serum IgE levels in WT mice but not in CD1−/− mice. Furthermore, administering IL-18 to WT mice caused the production of a significant amount of IL-4 and IL-13 whereas CD1−/− mice produced no IL-4 and diminished amounts of IL-13 (Fig. 1, C and D). These results suggest that CD4+ NK1.1+ T cells produce both IL-4 and IL-13 in response to IL-18.

NKT Cells Produce IL-4 and Express CD40L in Response to In Vivo Treatment with IL-18. To determine the roles of NKT cells in IL-18–induced IgE response, we directly tested whether CD4+ NK1.1+ T cells produce IL-4 and increase CD40L expression when WT mice are injected with IL-18. As shown in Fig. 2 A, CD4+ NK1.1+ T cells obtained from IL-18–injected mice, compared with PBS–injected mice, showed a significant increase (P < 0.01) in the proportion of T cells producing IL-4 ex vivo (7.1%). In contrast, few, if any, CD4+ NK1.1+ T cells contained cyto-
plasmic IL-4. Similarly, CD4⁺NK1.1⁺ T cells in IL-18–injected WT mice showed a significant increase \((p < 0.01)\) in the proportion of CD40L-expressing T cells (Fig. 2 B). Although IL-18 also caused an increase in the proportion of CD4⁺NK1.1⁻ T cells that expressed CD40L, the frequency of positive cells was significantly less than that among the CD4⁺NK1.1⁺ T cells.

**IL-18Rα Chain Expression on NKT Cells.** The responsiveness of CD4⁺NK1.1⁺ T cells to IL-18 suggested that these cells express IL-18R constitutively. We compared the expression of IL-18Rα chain on CD4⁺ NK1.1⁺ and CD4⁺NK1.1⁻ T cells by flow cytometric analysis using anti-IL-18Rα chain mAb. NK cells (CD4⁻ NK1.1⁺), which express high levels of IL-18Rα chain (24), were included as positive controls. Freshly prepared splenic CD4⁺ NK1.1⁺ T cells (Fig. 2 C, R2) constitutively express high levels of IL-18Rα chain (mean fluorescence intensity [MFI]: 11.0) whereas CD4⁺ NK1.1⁻ T cells (Fig. 2 C, R1) express only low levels (MFI: 3.9). Consistent with previous reports of ours (24) and others (11), NK cells (Fig. 2 C, R3) constitutively express high levels of IL-18Rα chain. They produce IL-13 but not IL-4 upon IL-18 stimulation in vitro (not depicted).

**IL-18 Stimulates NKT Cells to Produce IL-4, Express CD40L, and Enhance IgE Production by B Cells.** To further substantiate the capacity of CD4⁺ NK1.1⁺ and CD4⁺NK1.1⁻ T cells to produce IL-4 and express CD40L in response to IL-18, we sorted CD4⁺ NK1.1⁺ and CD4⁺NK1.1⁻ T cells and stimulated them with 200 μM IL-2 and/or 50 ng/ml IL-18 for 4 d. As shown in Fig. 3 A, CD4⁺ NK1.1⁺ T cells cultured with IL-18 and IL-2 produced significant amounts of IL-4 and IL-13 whereas conventional CD4⁺ NK1.1⁻ T cells produced little IL-4 and small amounts of IL-13. We also found that IL-18 plus IL-2 stimulates CD4⁺ NK1.1⁺ but not CD4⁺ NK1.1⁻ T cells to produce IL-9 (Fig. 3 A). CD4⁺ NK1.1⁺ T cells cultured with IL-18 and IL-2 produced modest amounts of IFN-γ (249 pg/ml), far less than that (5,381 pg/ml) stimulated by IL-18 and IL-12 (not depicted).

As shown in Fig. 3 B, IL-2 or IL-18 alone substantially increased CD40L expression on CD4⁺ NK1.1⁺ T cells (46.1 and 39.7%), but the combination caused profound induction (94.2%). In contrast, the same treatment of CD4⁺ NK1.1⁻ T cells only moderately induced CD40L, suggesting that CD4⁺ NK1.1⁺ T cells are the major targets of IL-18.

We also tested the capacity of CD4⁺ NK1.1⁺ T cells and CD4⁺ NK1.1⁻ T cells stimulated with IL-2 and IL-18 for 4 d to induce IgE in resting B cells in vitro. IL-2 plus IL-18–stimulated CD4⁺ NK1.1⁺ T cells were able to induce B cells to secrete IgE whereas conventional CD4⁺ NK1.1⁻ T cells failed (Table I). Taken together, these results indicate that NKT cells constitutively expressing IL-18Rα chain are a crucial subset of CD4⁺ T cells that respond to IL-18 by producing IL-4 and expressing CD40L, which in combination, induce IgE production by B cells both in vivo and in vitro.

**NKT Cells but Not Previously Activated CD4⁺ NK1.1⁻ T Cells Produce IL-4 in Response to IL-18.** In Fig. 3, we demonstrated that NKT cells but not CD4⁺NK1.1⁻ T cells are highly responsive to IL-18. To determine if the induction of Th2 cytokines and CD40L after IL-18 is a unique property of NKT cells or a property of all previously activated or memory T cells, we compared IL-18 responsiveness of NKT cells to that of previously activated

---

**Figure 2.** NKT cells produce IL-4 and express CD40L in response to in vivo treatment with IL-18. C57BL/6 mice were injected daily with IL-18 (2 μg/day) or PBS for 10 d (four mice per group). Intracellular IL-4 (A) or CD40L staining (B) of CD4⁺ NK1.1⁺ and CD4⁺NK1.1⁻ T cells was performed as described in Materials and Methods. Representative data are shown from four independent mice. The percentage shown represents the proportion of cells positive for cytoplasmic IL-4. Results are geometric means ± SD. *p < 0.01. (C) freshly prepared splenic cells from C57BL/6 mice were analyzed for expression of CD4 and NK1.1 by flow cytometry. IL-18Rα chain expression on CD4⁺ NK1.1⁺ (R1), CD4⁺ NK1.1⁻ (R2), and CD4⁺ NK1.1⁺ (R3) cells was analyzed as described in Materials and Methods. The number shown represents the MFI of IL-18Rα chain staining.
conventional CD4+ T cells. For this purpose, we used CD44high CD4+ T cells as a control population. Before comparison, we examined the expression of CD44 on total CD4+ T cells, CD4+ NK1.1+ T cells, and total CD4+ NK1.1- T cells obtained from normal C57BL/6 mice. As shown in Fig. 4 A, almost all freshly prepared CD4+ NK1.1+ T cells (R2) expressed high levels of CD44 whereas only 12.9 and 21.6% of CD4+ NK1.1- T cells (R3) and total CD4+ T cells (R1) expressed CD44, respectively.

Because a substantial proportion of CD44high CD4+ T cells obtained from normal C57BL/6 mice. As shown in Fig. 4 A, almost all freshly prepared CD4+ NK1.1+ T cells (R2) expressed high levels of CD44 whereas only 12.9 and 21.6% of CD4+ NK1.1- T cells (R3) and total CD4+ T cells (R1) expressed CD44, respectively.

Table I. Induction of IgE Production by B Cells Cocultured with IL-18 and IL-2–stimulated NKT Cells or Conventional CD4+

| Cells          | Culture conditions | IgE (ng/ml) |
|----------------|--------------------|-------------|
| CD4+ NK1.1- T cells | medium             | <10         |
|                | IL-2 plus IL-18    | <10         |
| CD4+ NK1.1+ T cells | medium             | <10         |
|                | IL-2 plus IL-18    | 90.1 ± 3.7  |

CD4+ NK1.1- and CD4+ NK1.1- T cells (10⁵/0.2 ml/well) from C57BL/6 mice were cultured with medium alone or 50 ng/ml IL-18 and 200 pM IL-2. After 4 d of culture, freshly purified C57BL/6 splenic B cells (10⁵/0.2 ml/well) were added with 10 µg/ml anti–IFN-γ antibody. After an additional 10 d of incubation, supernatants were harvested and IgE contents were measured by ELISA. Results are geometric means ± SD.

Figure 3. NKT cells produce IL-4, IL-9, and IL-13 and express CD40L in vitro in response to IL-18. Sorted CD4+ NK1.1+ and CD4+ NK1.1- T cells (10⁵/0.2 ml/well) from C57BL/6 mice were cultured with various combinations of 200 pM IL-2 and 50 ng/ml IL-18. After 4 d of culture, supernatants were harvested and tested for IL-4, IL-9, IL-13, and IFN-γ contents by ELISA (A) and surface expression of CD40L was analyzed by flow cytometry (B). The percentage shown represents the proportion of CD40L+ cells among CD4+ T cells. Results are geometric means ± SD. *, <10 pg/ml; **, <40 pg/ml.
CD4+ NK1.1− T Cells Are Required in IL-18–induced IgE Responses. Although conventional CD4+ NK1.1− T cells responded poorly to IL-18 in vivo and in vitro with relatively modest induction of IL-4 and CD40L, these results leave open the question of whether conventional CD4+ T cells are also required for the observed effect of IL-18 on IgE production. Thus, we tested IL-18 responsiveness of class II−/− mice expressing almost the same number of CD4+ NK1.1− T cells as were expressed by WT mice, although CD4+ T cells constituted only 4 to 5% of their spleen cells (Fig. 5 A; reference 20). As shown in Fig. 5 B, class II−/− mice completely failed to demonstrate induction of IgE in response to IL-18 treatment. However, class II−/− mice reconstituted with conventional CD4+ T cells from WT mice mounted a small but significant IgE response to IL-18 (Fig. 5 C) whereas those mice reconstituted with conventional CD4+ T cells from IL-4−/− mice failed to do so in response to IL-18 (Fig. 5 C). Compared with WT mice, class II−/− mice reconstituted with CD4+ T cells showed weak IgE responses, suggesting that host spleen was only partially repopulated. Indeed, only 0.94, 1.58, and 0.64% of transferred conventional T cells were repopulated at days 3, 7, and 10, respectively (Fig. 5 D). These results provide direct evidence that IL-4–producing conventional CD4+ T cells are needed for IgE production by B cells.

Discussion

Here we show that the administration of IL-18 results in increases in serum levels of IgE, IL-4, and IL-13 in normal mice but not in CD1−/− mice, which lack NKT cells (Fig. 1). In addition, NKT cells, which are strongly positive for the IL-18Rα chain, produce IL-4, IL-9, and IL-13 and express CD40L in response to IL-18 plus IL-2 in the absence of TCR engagement (Figs. 2 and 3). Furthermore, NKT cells that are stimulated with IL-18 and IL-2 for 4 d promote class
The novel lymphoid lineage, NKT cells, which expresses both NK receptors and TCR encoded by the Vα14 and Jα281 gene segments, has been suggested to play an important role in the regulation of immune responses (17). Cytokines such as IL-12 can stimulate NKT cells to release IFN-γ and exhibit natural cytotoxicity (29, 30). Recent studies demonstrated that NKT cells could transactivate NK cells via IFN-γ production upon stimulation with CD1d-bound glycolipid Lα-GalCer; reference 18). This IFN-γ production by NKT cells in response to α-GalCer is predominantly mediated by IL-12 produced by dendritic cells (31). Moreover, α-GalCer-stimulated NKT cells inhibit antigen-induced allergic responses by production of IFN-γ.

Figure 5. Transfer of conventional CD4+ T cells from WT mice partially reconstitutes IgE production by class II−/− mice injected with IL-18. (A) Frequency of CD4+ NK1.1+ T cells in total spleen cells (top) and CD4-enriched spleen cells (bottom) from C57BL/6, CD1−/−, and class II−/− mice. Percent of cells in selected quadrants are indicated. C57BL/6 and class II−/− mice received either nothing (B) or 10^7 CD4+ NK1.1+ T cells from WT or IL-4−/− mice (C; five mice per group) and were injected daily with IL-18 (2 µg/day) for 13 d. Mice were bled on days 0, 7, 10, and 14 and serum IgE was measured by ELISA. (D) Class II−/− mice (three mice per group) received an intravenous injection of 10^7 CFSE-labeled CD4+ T cells from C57BL/6 mice. Spleen cells were isolated from recipients at various times after transfer and transferred cells were identified by CSFE fluorescence as described in Materials and Methods.
The Journal of Experimental Medicine

production by both NKT and conventional CD4+ T cells. Nevertheless, our finding indicates that IL-4 efficiently and are unable to completely reconstitute IgE responses in certain situations and Th2 responses in others. The data presented here show that among CD4+ T cells, NKT cells have the unique capacity to respond to IL-18 by IL-4 production and CD40L up-regulation and directly help B cells produce IgE in vitro and in vivo without antigenic stimulation. However, our studies with class II−/− mice reveal that conventional CD4+ T cells are also required for the observed effect of IL-18 on IgE production (Fig. 5). Class II−/− mice reconstituted with conventional CD4+ T cells from WT mice but not from IL-4−/− mice mounted a small but significant IgE response to IL-18 (Fig. 5 C), suggesting that conventional T cells participate in IgE induction by secreting a small amount of IL-4. However, this IgE production in WT CD4+ T cell reconstituted mice failed to increase beyond day 10 after IL-18 administration. We suspect that the failure to completely reconstitute IL-18–induced IgE responses in these animals is due to incomplete repopulation of CD4+ T cells in class II−/− hosts (Fig. 5 D). We could increase the number of repopulated cells by increasing the number of transferred cells, although we could not increase repopulation rate (unpublished data). Thus, in the absence of class II expression, CD4+ T cells may not survive efficiently and are unable to completely reconstitute IgE production. Nevertheless, our finding indicates that IL-4 production by both NKT and conventional CD4+ T cells is critical for IL-18–induced IgE production. However, as NKT cells and conventional T cells produce large and small amounts of IL-4, respectively, the precise role of IL-4 from conventional T cells in B cell activation remains uncertain. Furthermore, we do not know the appropriate ratio of NKT cells to conventional T cells in effective B cell IgE responses.

We have shown that KIL-18Tg and KCASP1Tg mice, which overexpress mature IL-18 or caspase-1 gene, respectively, in keratinocytes, spontaneously produce IgE in an endogenous IL-18–dependent manner (10, 15, 16). Interestingly, our recent examination of KCASP1Tg mice revealed that they exhibited a two- to threefold increase in splenic NKT cells, although short-term in vivo treatment with IL-18 did not affect the number of splenic NKT cells (unpublished data). These increases in the proportion of splenic NKT cells and serum IgE levels in KCASP1Tg mice are somewhat similar to that in the Vα14-Jα281 Tg mice established by Bendelac et al. (33). These Vα14-Jα281 Tg mice exhibit a selective increase in serum IgE (sixfold above controls on average) and IgG1 (twofold above controls). Here, we have provided strong evidence that CD1d-restricted NKT cells are critically important for the induction of IgE in response to IL-18. However, as NKT cells that express TCR other than Vα14-Jα281 TCR are also selected by CD1d (34), it remains possible that such nonclassical NKT cells also contribute to the IL-18–induced IgE response. Future studies with Jα281−/− mice should be able to resolve this issue.

Recently, Leite-de-Maraes et al. (35) have reported that IL-18 enhances IL-4 production by L-activated NKT cells but not by conventional T cells. Thus, IL-18 enhances anti-CD3 Ab– or α-GalCer–induced IL-4 production by NKT cells. However, IL-18 also enhanced IFN-γ production by NKT cells stimulated with anti-CD3 or α-GalCer. These results suggest that IL-18 exerts its action on IL-4 production by NKT cells by amplifying the signaling pathway initiated by TCR/CD3 cross-linkage or cognate L-α-GalCer. In sharp contrast, our results reveal that IL-18 and IL-2 synergistically and directly exert IL-4 and CD40L–inducing activities on NKT cells even in the absence of TCR engagement. Furthermore, these activated NKT cells in collaboration with IL-4–producing conventional T cells can induce class switching to IgE in B cells, indicating a new function of NKT cells in innate immunity. These findings suggest that IL-18 and NKT cells might be potential targets in the effort to develop agents that regulate Th2-independent allergic disorders as innate type allergic response. Furthermore, as IL-18 predominantly enhances production of Th2 cytokines both in vitro and in vivo, injection of IL-18 might be promising for the treatment of Th1 diseases such as insulin dependent diabetes mellitus.

We express sincere thanks to Hayashibara Biochemical Laboratories Inc. for providing us with recombinant murine IL-18 and anti–IL-18R chain mAb.

This study is supported by Grant-in-Aid for Scientific Research on Priority Areas and a Hitech Research Center grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Submitted: 26 September 2002
Revised: 14 February 2003
Accepted: 21 February 2003

References

1. Okamura, H., H. Tsutsui, T. Komatsu, M. Yutsudo, A. Hakura, T. Tanimoto, K. Torigoe, T. Okura, Y. Nukada, K. Hattori, et al. 1995. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature. 378:88–91.

2. Gu, Y., K. Kuida, H. Tsutsui, G. Ku, K. Hsiao, M.A. Fleming, N. Hayashi, K. Higashino, H. Okamura, K. Nakashima, et al. 1997. Activation of interferon-γ inducing factor mediated by interleukin-1B converting enzyme. Science. 275:206–209.

3. Robinson, D., K. Shibuya, A. Mui, F. Zonin, E. Murphy, T. Sana, S.B. Hartley, S. Menon, R. Kastelein, F. Bazan, et al. 1997. IGIF dose not drive Th1 development but synergizes with IL-12 for interferon-γ production and activates IRAK and NFκB. Immunity. 7:571–581.

4. Yoshimoto, T., K. Takeda, T. Tanaka, K. Ohkusu, S. Kawai, H. Okamura, S. Akira, and K. Nakashima. 1998. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-γ production. J. Immunol. 161:3400–3407.

5. Yoshimoto, T., H. Okamura, Y-I. Tagawa, Y. Iwakura, and K. Nakashima. 1997. Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-γ production from activated B cells. Proc. Natl. Acad. Sci. USA. 94:3948–3953.
10. Yoshimoto, T., H. Mizutani, H. Tsutsui, N. Noben-Trauth, H.A. Young. 1999. IL-18 induction of IgE: dependence on CD4+ T cells, IL-4 and STAT6. *Nat. Immunol.* 1:132–137.

11. Yoshimoto, T., H. Mizutani, H. Tsutsui, N. Noben-Trauth, K. Yamanaka, M. Tanaka, S. Izumi, H. Okamura, W.E. Paul, and K. Nakanishi. 2000. IL-18 induction of IgE: dependence on CD4+ T cells, IL-4 and STAT6. *Nat. Immunol.* 1:132–137.

12. Hoshino, T., H. Yagita, J.R. Ortaledo, R.H. Wiltrout, and H.A. Young. 2000. *In vivo* administration of IL-18 can induce IgE production through Th2 cytokine induction and up-regulation of CD40 ligand (CD154) expression on CD4+ T cells. *Eur. J. Immunol.* 30:1998–2006.

13. Nakanishi, K., T. Yoshimoto, H. Tsutsui, and H. Okamura. 2001. Interleukin-18 regulates both Th1 and Th2 responses. *Annu. Rev. Immunol.* 19:423–474.

14. Chikano, S., K. Sawada, T. Shimoyama, A. Sugihara, K. Sekitawa, N. Terada, K. Nakanishi, and H. Okamura. 2000. IL-18 and IL-12 induce intestinal inflammation and fatty liver in mice in an IFN-γ-dependent manner. *Gut.* 47:779–786.

15. Yamanaka, K., M. Tanaka, H. Tsutsui, T.S. Kupper, K. Ashi, H. Okamura, K. Nakanishi, M. Suzuki, N. Kayagaki, R.A. Black, et al. 2000. Skin-specific caspase-1 transgenic mice show cutaneous apoptosis and pre-endotoxin shock conditions. *J. Exp. Med.* 199:11340–11345.

16. Konishi, H., H. Tsutsui, T. Murakami, S. Yumikura-Futatsugi, K. Yamanaka, M. Tanaka, Y. Ikawara, N. Suzuki, E.V. Fuchs, K. Takeda, et al. 2002. IL-18 contributes to the spontaneous development of atopic dermatitis-like inflammatory skin lesion independently of IgE/stat6 under specific pathogen-free conditions. *Proc. Natl. Acad. Sci. USA.* 99:11340–11345.

17. Bendelac, A., M.N. Rivera, S.-H. Park, and J.H. Roark. 1997. Mouse CD1-speciﬁc NK1 T cells: development, speciﬁcity, and function. *Annu. Rev. Immunol.* 15:535–562.

18. Kawanoo, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, et al. 1997. CD1d-restricted and TCR-mediated activation of Vα14 NK T cells by glycosylceramides. *Science.* 278:1626–1629.

19. Yoshimoto, T., and W.E. Paul. 1994. CD4+ NK1.1+ T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. *J. Exp. Med.* 179:1285–1295.

20. Yoshimoto, T., A. Bendelac, C. Watson, J. Hu-Li, and W.E. Paul. 1995. Role of NK1.1+ T cells in a T1α2 response and in immunoglobulin E production. *Science.* 270:1845–1847.

21. Singh, N., S. Hong, D.C. Scherer, I. Sertizawa, N. Burdin, M. Kronenberg, Y. Koezuka, and L. Van Kaer. 1999. Activation of NK T cells by CD1d and α galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. *J. Immunol.* 163:2373–2377.

22. Burdin, N., L. Brossay, and M. Kronenberg. 1999. Immunization with α galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. *Eur. J. Immunol.* 29:2014–2025.

23. Mendiarrate, S.K., W.D. Martin, S. Hong, A. Boesteau, S. Joyce, and L. Van Kaer. 1997. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. *Immunity.* 6:469–477.

24. Hyodo, Y., K. Matsu, N. Hayashi, H. Tsutsui, S. Kashiwamura, H. Yamauchi, K. Hiroishi, K. Takeda, Y. Tagawa, Y. Ikawara, et al. 1999. IL-18 up-regulates perforin-mediated NK activity without increasing perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor. *J. Immunol.* 162:1662–1668.

25. Lyons, A.B., and C.R. Parish. 1994. Determination of lymphocyte division by flow cytometry. *J. Immunol. Methods.* 171:131–137.

26. Chen, H., H. Huang, and W.E. Paul. 1997. NK1.1+CD4+ T cells lose NK1.1 expression upon in vitro activation. *J. Immunol.* 158:5112–5119.

27. Finkelman, F.D., J. Holmes, I.M. Katona, J.F. Urban, Jr., M.P. Beckmann, L.S. Park, K.A. Schooley, R.L. Coffman, T.R. Mosmann, and W.E. Paul. 1990. Lymphokine control of in vivo immunoglobulin isotype selection. *Annu. Rev. Immunol.* 8:303–333.

28. Galli, S.J., and C.S. Lantz. 1999. Fundamental Immunology. Lippincott, Philadelphia. 1127 pp.

29. Takeda, K., S. Seki, K. Ogawara, R. Anzai, W. Hashimoto, K. Sugiyama, M. Takahashi, M. Satoh, and K. Kamigai. 1996. Liver NK1.1+CD4+ αβ T cells activated by IL 12 as a major effector in inhibition of experimental tumor metastasis. *J. Immunol.* 156:3366–3373.

30. Cui, J., T. Shin, T. Kawano, H. Sato, E. Kondo, I. Toura, Y. Kaneko, H. Koseki, M. Kanno, and M. Tamiguchi. 1997. Requirement for V α14 NK T cells in IL-12-mediated rejection of tumors. *Science.* 278:1623–1626.

31. Kitamura, H., K. Ikawabe, T. Yahata, S. Nishimura, A. Ohta, Y. Ohmi, M. Sato, K. Takeda, K. Okumura, L. Van Kaer, et al. 1999. The natural killer T (NK T) cell ligand α galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL-12) production by dendritic cells and IL-12 receptor expression on NK T cells. *J. Exp. Med.* 189:1121–1128.

32. Cui, J., N. Watanabe, T. Kawano, M. Yamashita, T. Kamata, C. Shimizu, M. Kimura, E. Shimizu, J. Koike, H. Koseki, et al. 1999. Inhibition of T helper cell type 2 cell differentiation and immunoglobulin E response by ligand-activated Vα14 natural killer T cells. *J. Exp. Med.* 190:783–792.

33. Bendelac, A., R.D. Hunziker, and O. Lantz. 1996. Increased CD1d-restricted and TCR-mediated activation of Vα14 NK T cells by glycosylceramides. *Science.* 272:1626–1629.

34. Skold, M., N.N. Faizunnessa, C.R. Wang, and S. Cardell. 1999. CD1d-specific NK1.1+ T cells with a transgenic variant TCR. *J. Immunol.* 165:1618–174.

35. Leite-De-Moraes, M.C., A. Hameg, M. Pacilio, Y. Koezuka, M. Tamiguchi, L. Van Kaer, E. Schneider, M. Dy, and A. Herbelin. 2001. IL-18 enhances IL-4 production by ligand activated NK T lymphocytes: a pro-Th2 effect of IL-18 exerted through NK T cells. *J. Immunol.* 166:945–951.